Education
About Us
Working with TipRanks
Follow Us
Aspen Pharmacare (APNHY)
:APNHY
APNHY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.01 - $13.85
Previous CloseN/A
Volume14.00
Average Volume (3M)11.00
Market Cap
$3.07B
Enterprise Value$78.67B
Total Cash (Recent Filing)$12.34B
Total Debt (Recent Filing)Rs36.46B
Price to Earnings (P/E)12.2
Beta0.36
Next Earnings
Sep 03, 2025EPS EstimateN/A
Last Dividend Ex-Date
Sep 20, 2024Dividend Yield0.27%
Share Statistics
EPS (TTM)0.35
Shares Outstanding446,252,320
10 Day Avg. Volume0
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio6.51
Price to Book (P/B)0.59
Price to Sales (P/S)0.00
P/FCF Ratio18.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.50Price Target Upside11.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Aspen Pharmacare News
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
99.99% Public Companies and
Individual Investors
APNHY FAQ
What was Aspen Pharmacare’s price range in the past 12 months?
Aspen Pharmacare lowest stock price was $6.01 and its highest was $13.85 in the past 12 months.
What is Aspen Pharmacare’s market cap?
Aspen Pharmacare’s market cap is $3.07B.
When is Aspen Pharmacare’s upcoming earnings report date?
Aspen Pharmacare’s upcoming earnings report date is Sep 03, 2025 which is in 39 days.
How were Aspen Pharmacare’s earnings last quarter?
Aspen Pharmacare released its earnings results on Mar 03, 2025. The company reported $0.347 earnings per share for the quarter, beating the consensus estimate of N/A by $0.347.
Is Aspen Pharmacare overvalued?
According to Wall Street analysts Aspen Pharmacare’s price is currently Undervalued.
Does Aspen Pharmacare pay dividends?
Aspen Pharmacare pays a Annually dividend of $0.2 which represents an annual dividend yield of 0.27%. See more information on Aspen Pharmacare dividends here
What is Aspen Pharmacare’s EPS estimate?
Aspen Pharmacare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspen Pharmacare have?
Aspen Pharmacare has 446,252,320 shares outstanding.
What happened to Aspen Pharmacare’s price movement after its last earnings report?
Aspen Pharmacare reported an EPS of $0.347 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 11.718%.
Which hedge fund is a major shareholder of Aspen Pharmacare?
Currently, no hedge funds are holding shares in APNHY
Aspen Pharmacare Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.50 (11.28% Upside)
$7.50 (11.28% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.99%
12-Months-Change
Fundamentals
Return on Equity
5.32%
Trailing 12-Months
Asset Growth
-4.96%
Trailing 12-Months
Company Description
Aspen Pharmacare
Aspen Pharmacare Holdings Limited is a global specialty and branded pharmaceutical company, recognized as Africa's largest drug manufacturer. Established in South Africa, Aspen has a diverse portfolio that includes prescription medicines, consumer health products, and active pharmaceutical ingredients (APIs). The company's operations span multiple sectors, including anesthetics, thrombosis, and high potency and cytotoxic products, serving both developed and emerging markets worldwide.
APNHY Company Deck
APNHY Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Aspen's earnings call highlighted significant achievements, particularly in revenue and EBITDA growth, successful acquisitions, and promising opportunities in the GLP-1 market. However, challenges such as currency impacts, difficulties in China, and increased tax and working capital levels posed notable concerns.Read More>Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Amneal Pharmaceuticals
―